Prof. Dr. Stefan Willich, Director, Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Centre, Berlin

13:30-13:50    

Welcome Address

After completing his medical studies in Berlin, Munich, and New York, Professor Willich obtained a Master of Public Health degree from Harvard University, an MBA degree from INSEAD and a board certification in internal medicine. From 1993 to 1995, he served as acting chair of epidemiology at the University of Greifswald and as visiting professor at Harvard University. In 1995, he was appointed to his current position at the Charite. In addition to his work in medicine, Stefan Willich is an avid and accomplished musician, as well as the founder and conductor of the World Doctors Orchestra.

Founded over 300 years ago, the Charité is today one of the largest university hospitals in Europe. It extends over four campuses with more than 100 clinics and over 13,000 employees, including 3,800 doctors and scientists.

Dr. David-Alexandre Gros, Chief Strategy Officer, Sanofi

13:50-14:30

Keynote Address

Dr. Gros is responsible for business development and acquisition activities as well as strategic planning, economic evaluation of projects, strategic intelligence, and alliance management. He brings a wealth of experience to Sanofi as a physician, strategic consultant and investment banker. He joins after serving as a key advisor to pharmaceutical, biotechnology and diagnostic companies as a Principal and founding member of the Healthcare Investment Banking practice at Centerview Partners, in San Francisco, California. He previously worked as Vice President at Merrill Lynch serving healthcare clients on a wide range of strategic, corporate finance and merger & acquisition issues. He started his advisory career at McKinsey & Company in 2002 as an Associate, was promoted to Engagement Manager in 2004 and to Associate Principal in 2006.

David-Alexandre began his career in medicine, acquiring clinical experience as a Resident Physician at the University of Pennsylvania Health System from 1999 to 2000, and working in clinical and health outcomes research at the Department of Urology of the Johns Hopkins Hospital from 1996 to 1999. David-Alexandre holds a B.A. from Dartmouth College (1995), an M.D. from Johns Hopkins University School of Medicine (1999), and an MBA from Harvard Business School (2002).

Harald F. Stock, PhD, Chief Executive Officer, Grünenthal

14:30-15:00

Interview Session with Elsevier Business Intelligence

In January 2009 Dr. Harald F. Stock was appointed Chief Executive Officer of the Grünenthal Group. As an independent, family-owned corporation, Grünenthal is passionate about being the preferred partner in pain management worldwide, thus contributing to people's health and quality of life. The company has a direct presence in 36 countries in Europe, Australia, and Latin America and reached revenues of EUR 910mn in 2010.

Harald F. Stock also serves as a Board Observer on the Board of Directors of ConforMIS, Inc., Burlington, MA, USA, as a Member of the Board for immatics biotechnologies GmbH, Tübingen, Germany, and as Vice-Chairman of the Board of Directors of PAION AG, a biopharmaceutical company headquartered in Aachen, Germany. He started his career in Health Care as a Key Account Manager at Hestia Pharma. Thereafter he held various positions of increasing responsibilities in local and global functions and corporate divisions of the Roche Group, until in 2005 he was appointed Senior Vice President of the global Near Patient Testing business in Graz. From 2006 until end of 2008 he was Chairman and Managing Director of the German DePuy Group, the Orthopaedics Division of Johnson & Johnson. He studied Chemistry and Business Administration in the USA, Great Britain and Germany and received a PhD. in inorganic chemistry from University of Heidelberg in 1997.

Lauren Mathys, Founder, Bluecrest Consulting

17:00-17:40

Blue Ocean Strategy

Lauren Mathys coaches, consults and trains organizations to apply Blue Ocean Strategy (BOS) thinking, a published and internationally recognized approach to defining strategies through the creation of uncontested market space. Prior to starting Bluecrest Consulting, she worked for 20 years in the pharmaceutical industry, most recently as Vice President Strategic Marketing at Merck Serono. Lauren Mathys holds a bachelor's degree from Occidental College and an MBA degree from INSEAD.

Bluecrest Consulting helps companies to apply BOS frameworks and use the BOS toolkit to go beyond traditional approaches to strategy development.

David Ewing Duncan, Director Center for Life Science Policy, UC Berkeley

21:00 During the Dinner Session

"What Our Bodies Reveal About Our Future"

David Ewing Duncan is an award-winning, best-selling author of seven books published in 19 languages; he is a journalist and a television, radio and film producer and correspondent. His most recent book is the bestseller Experimental Man: What one man's body reveals about his future, your health, and our toxic world. He is the Chief Correspondent of public radio's Biotech Nation; and a columnist for Fortune. He is the Director of the Center of Life Science Policy at UC Berkeley.

David writes for The New York Times, National Geographic, Harper's, Atlantic Monthly, the San Francisco Chronicle, and many other publications. He has won numerous awards including the Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing. He is a graduate of Vassar College and now lives in San Francisco.

Dr. Chandra P. Leo, Partner, HBM Partners and President, INSEAD Healthcare Alumni Network

Summit Chair

Dr. Chandra P. Leo has worked in venture capital / private equity since 2001, focusing on investments in biotech/pharma and medical devices. He is a member of the private equity team at HBM Partners, a global investor in healthcare and life science companies. As such, Dr. Leo is responsible for HBM's investments in several private companies in the United States and Europe.

He previously practiced as a physician in Leipzig, Germany, and worked as a postdoctoral scientist at Stanford University. Dr. Leo attended medical school at the Freie Universität Berlin (Charité) and King's College London and holds an MBA degree from INSEAD.

He currently serves as President of the INSEAD Healthcare Alumni Network which he co-founded in 2006.

Gilbert Achermann, Chairman of the Board of Directors, Straumann and Siegfried

Gilbert Achermann has been a member of the Board of Directors at Straumann since 2009 and was appointed Chairman of the Board in 2010. He joined Straumann in 1998 as Chief Financial Officer and was appointed President and Chief Executive Officer in 2002. Formerly, he served for 13 years at UBS in Zurich, Geneva, New York and Frankfurt, where he worked in Corporate Finance, Sales & Trading. Gilbert Achermann is also Chairman of the Board of Siegfried Holding AG, Zofingen. Other key assignments include the Board of Directors and Board of Trustees of the independent academic network International Team for Implantology (ITI) as well as the advisory boards for International Cooperation of the Canton Basel-Stadt and for the Basel Association of Statistics and Economy.

Gilbert Achermann holds an Executive MBA from IMD in Lausanne and a degree from the HWV business school in St. Gallen.

Andreas R. Krebs, Chairman of the Supervisory Board, Merz

Andreas R. Krebs is the Chairman of the Supervisory Board of Merz and a Member of the Supervisory Board of Wilex. Until October 2009, he worked for Wyeth Pharmaceuticals, most recently as a member of the group's Board of Directors and President of Europe, Middle East, Africa and Canada Operations. Prior to joining Wyeth, he spent 19 years at Bayer AG. He is currently the Managing Director and partner of Cologne Invest GmbH and works independently for various companies in the pharmaceutical industry.

Merz is an independent German pharmaceutical company with its own research and development, focused on drugs for the treatment of illnesses in the fields of neurology, psychiatry. Another field of competence is clinical and aesthetic dermatology.

Pr. Bernat Soria, Director of Department of Stem Cells in CABIMER and former Minister of Health, Spain

Professor Bernat Soria, MD, PhD Former Minister of Health and Consumer Affairs of Spain (2007-2009), is currently the Director of the Department of Stem Cells in CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine in Seville, Spain). He was previously the Director of CABIMER and a Professor of Regenerative Medicine at the University Pablo de Olavide in Seville. 

He graduated from Valencia and completed his postdoctoral studies at the Max Plank Institute for Biophysical Chemistry and at the University of East Anglia, School of Biological Sciences. He has been a Visiting Professor in the National University of Singapore, the Chairman of the European Stem Cell Network end the President of the European Association of Biophysical Societies. He has previously held posts such as the Presidency of the Spanish Society of Diabetes, the Spanish Society of Biophysics and the Spanish Society of Physiological Sciences.

Bernat Soria has published more that 100 papers and edited 4 books. Among others he has received the Award and Gold Medal from the Royal Academy of Medicine, the National Research Award from the Spanish Diabetes Association and the Galien International Prize.

Dr. Andreas Abt, Director General, Roche Spain

Dr. Andreas Abt has spent the last decade at Roche, in a succession of management positions and is now General Manager of Spain.  Previously, he was General Manager in Belgium, and has held positions in Sales & Marketing, Commercial (Oncology), and Lifecycle Management. 

Dr. Abt completed his medical degree at the Universität Basel and obtained an MBA from INSEAD in 1999.

Aleksandar Ruzicic, Senior Principal, IMS Consulting Group

Moderator of the Incumbents Panel

Aleksandar Ruzicic has worked in consulting since 1994, focusing on life sciences/healthcare, particularly the pharmaceutical/biotech sector. He is a Senior Principal at IMS Consulting Group, the world's leading, specialized advisor on critical strategic and commercial issues in life sciences. He advises international pharmaceutical/biotech, medical devices and other companies in the healthcare sector on strategic and operational topics from R&D to marketing and sales, particularly on new business models, and has published his insights continuously in a series of reports and articles.

Mr. Ruzicic has obtained a Master of Science in Chemistry from University of Zürich and holds an MBA degree from INSEAD.

He currently serves as Vice President of the INSEAD Healthcare Alumni Network which he co-founded in 2006 and as President of the INSEAD Swiss Healthcare Industry Club.

Andre-Michel Ballester, CEO of the Sorin Group

Day 2, 13:30-13:50

Interview Session with the Healthcare Alumni Network

In 2007, Andre-Michel Ballester was appointed CEO of the Sorin Group, the largest European cardiovascular company and world leader in medical technology for cardiac surgery. From 2004 to 2007, he has been President of the Cardiac Rhythm Management Business Unit of the Sorin Group. Mr. Ballester was, from 2000 to 2004, Corporate Vice President EMEA, Asia and Latin America for Edwards Lifesciences. For over ten years prior to Edwards' spin-off from Baxter, he also held several executive positions in Europe and in the USA, and was appointed President, CardioVascular Group, Europe in 1997.

Born in Orleansville, Algeria, and raised in France, Mr. Ballester received his MS degree in Engineering from Ecole Centrale, Lille, France, and his MBA from INSEAD, Fontainebleau, France.

Pr. Stephen Chick, INSEAD Healthcare Management Initiative

Day 2, 14:00-14:20

15 Years of the INSEAD Healthcare Management Initiative

Stephen Chick is Professor of Technology and Operations Management at INSEAD and Academic Director of the INSEAD Healthcare Management Initiative. He also holds the Novartis Chaired Professor of Healthcare Management at INSEAD and is Executive Education Programme Director of the Middle East Health Leadership Programme. 

He received his MSc and PhD from the University of California at Berkeley in Industrial Engineering and Operations Research and his BSc in Mathematics from Stanford University. Prior to joining INSEAD, he taught process modelling, simulation and information systems at the University of Michigan.

Dr. Joe Tabet, Managing Partner, Melcion Chassagne & Company

Day 2, 14:00-14:20

15 Years of the INSEAD Healthcare Management Initiative

Dr. Tabet is currently Managing Partner at Melcion Chassagne & Cie, a team of business advisors that help Entrepreneurs succeed in their venture and maximise the value they capture.  He is additionally a lecturer at INSEAD / CEDEP and Cranfield University.  While at INSEAD, he founded the Healthcare Management Initiative in 1993.

Dr. Tabet holds holds a Medical Doctorate from St Joseph University in Beirut, a degree in surgery from the University of Paris, and an MBA from INSEAD.

Bernard Munos, Founder, InnoThink Center

14:20-15:00

Capstone Address

Mr. Munos is the founder and chief apostle of InnoThink, a partnership dedicated to bringing evidence-based innovation models to the pharmaceutical industry and its stakeholders. Before that, he was advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of the industry R&D model. His research, which has been published in Nature and Science, has helped stimulate a broad rethinking of the pharmaceutical business model by companies, investors, policymakers, regulators, and patient advocates.

He has presented his findings at numerous meetings sponsored by the National Academies, the Institute of Medicine, the President's Cancer Panel, the NIH Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, Genome Canada, the American Chemical Society, and the Council for American Medical Innovation as well as leading universities and think-tanks in the U.S. and Europe.

He received his MBA from Stanford University and holds other graduate degrees in economics and animal science from the University of California at Davis and the Institut National Agronomique in Paris, France.

Steven Flostrand, Principal, IMS Consulting Group

Day 2 Summit Chair

With more than ten years' experience in the pharmaceutical industry, as well as eight years' experience in consulting, Steven has a strong perspective on the challenges and opportunities that face companies seeking to commercialise new drugs.  He has worked to build businesses and launch drugs in markets as diverse as Russia and the USA, while holding positions in affiliate, regional and headquarter teams.  In the past few years, he has focused exclusively on matters of pricing and market access, and he recently joined IMS Consulting Group to further the development of their Centre of Excellence in this area.

Steven completed a Bachelor of Commerce degree (with honours) at the University of British Columbia and holds an MBA degree from INSEAD.

Eduardo Bravo, Managing Director and CEO, Tigenix

Eduardo Bravo has more than 18 years of experience in the pharmaceutical industry. His professional career includes several senior management positions at Sanofi-Aventis, including Vice President for Latin America, Marketing and Sales Manager for Europe and General Manager for Belgium. He also worked for 7 years at SmithKline Beecham in sales positions both nationally and internationally. Mr. Bravo holds a degree in Business Administration and an MBA degree from INSEAD.

TiGenix NV is a public biomedical company that focuses on ‘Living Medicines'. The company is exploiting the power of cell therapy and regenerative medicine to develop durable treatments for damaged and diseased tissues.

Elan Dekel, CEO, Medico.com

Elan Dekel is the Founder & CEO of Medico.com, Inc. Before, he spent 6½ years at Google. His last role was Head of Product for Africa, Middle East, and Eastern Europe. Before Google, Elan was the Founder and CEO of a YouTube predecessor named Earthnoise. Elan has also worked as a software engineer and as an investment manager at a VC fund. Elan holds a BSc. in Computer Science from Yale, and an MBA from INSEAD.

Launched in 2020, Medico.com's aim is to become the most trusted site for consumers to research health information, and to become well-informed and active drivers of their own health. Medico.com was initially launched in Spain, with the goal to expand to Latin America, India and other markets this year.

Dr. Tim H. Jessen, Managing Director, Bionamics

Timm Jessen is Managing Director of Bionamics plc, an asset management company set up to identify, develop and commercialize innovative projects in the Life Science arena. Bionamics currently manages the NEU² consortium, focusing on neurological diseases, especially Multiple Sclerosis.  From 1997-2004 Dr. Jessen was Chief Scientific Officer of the listed biotech company Evotec AG (Hamburg, Oxford), a technology and service provider to the pharmaceutical industry. Before that Dr. Jessen worked for six years in the pharmaceutical industry (sanofi-aventis) in pre-clinical research and alliance management. 

Dr. Jessen studied chemistry and biochemistry. He received his education and scientific career in Kiel, Munich, Cambridge/UK and Boston/US. He is married, has two children and lives in the North of Germany.

Dr. Ewald Walgenbach, Managing Partner, BC Partners

Ewald Walgenbach is Managing Partner at the private equity house BC Partners in Hamburg. In 2008 he joined from Bertelsmann AG where he has been a board member and CEO of the Direct Group division for five years after serving as COO for the group. He previously held senior positions at RTL Group, UFA Film+Fernseh, Bertelsmann AG and Boehringer Ingelheim, after spending six years with the Boston Consulting Group. He holds a degree in biology from the University of Cologne and a doctoral degree from the Max Planck Institute for Plant Breeding Research.

BC Partners is a leading private equity firm that has completed over 70 acquisitions in companies with a total enterprise value of €70 billion. Their portfolio includes Synlab, one of Europe's leading providers of laboratory diagnostics services.

Dr. Ulrich Thess, Managing Partner, Civitas International

Moderator

Ulrich is a Partner at Civitas International in Munich.  Prior to this, he was the Head of the German Healthcare Practices of Russell Reynolds Associates and Egon Zehnder International. Before that he was the CEO of the Deutsche Klinik für Diagnostik GmbH, a subsidiary of Rhön-Kliniken AG.

He began his professional career as a Management Consultant at Boston Consulting Group in Munich, where he last held the position of Senior Manager of the healthcare practice. Ulrich Thess completed his study of medicine as a licensed physician at the Universities of Bonn and Munich, earning the degree of Dr. med. He went on to earn his MBA at the INSEAD/Fontainebleau.

He currently serves as a Vice President of the INSEAD Healthcare Alumni Network which he co-founded in 2006

Workshop 1 Coordinator: Robert van Schagen (IEP'02), Programme Manager, Achmea.

Lean Healthcare - Doing it the Toyota Way

Robert Van Schagen is a specialist in health care economics and Programme Manager at Achmea, an integrated financial services group whose core business is insurance (life, non-life and health) and services relating to pensions and health.

Robert has deep experience in the field of health care financing, having served as Acquisition Manager Health Care Real Estate at Syntrus Achmea Vastgoed, Director at Meavita Dienstencentrum, Chairman Business Unit Care at Medisch Centrum Haaglanden and Manager P&C department at Medisch Centrum Haaglanden.

He has completed the PED programme at IMD (International Institute for Management Development) in Switzerland, the IEP at INSEAD and a Masters in Health Sciences at the Universiteit Maastricht.

Workshop 2 Coordinator: Dr. Roman Rittweger (MBA 94D), Roman Rittweger Advisors in Healthcare

New Models for Payer-Pharma Cooperation

Dr. Rittweger, has a medical degree and received an MBA from INSEAD in Fontainebleau. For several years he gained consulting experience at A.T.Kearney and McKinsey & Company. Roman Rittweger founded and managed ArztPartner almeda AG, an innovative service provider for payers and a market leader in disease management, which was taken over 2001 by DKV AG (Europe's largest private health insurance). He was one of the pioneers of disease management and managed care in Germany. After ArztPartner almeda, Roman Rittweger joined BBDO Consulting as a Managing Partner responsible for healthcare. His enthusiasm for "healthcare-branding" originated from the confrontation with increasing competition in all sectors of healthcare. Since the foundation of "Roman Rittwerger - Advisors in Healthcare", Roman Rittweger and his teams support Fortune 500 and Dax companies as well as successful SMEs in mastering a variety of market challenges.

Workshop 3 Coordinator: Dr. Chandra P. Leo (MBA 02D), Partner, HBM Partners

The Role of Private Equity in Healthcare

Dr. Chandra P. Leo has worked in venture capital / private equity since 2001, focusing on investments in biotech/pharma and medical devices. He is a member of the private equity team at HBM Partners, a global investor in healthcare and life science companies. As such, Dr. Leo is responsible for HBM's investments in several private companies in the United States and Europe.

He previously practiced as a physician in Leipzig, Germany, and worked as a postdoctoral scientist at Stanford University. Dr. Leo attended medical school at the Freie Universität Berlin (Charité) and King's College London and holds an MBA degree from INSEAD.

He currently serves as President of the INSEAD Healthcare Alumni Network which he co-founded in 2006.

Workshop 4 Coordinator: Marc Molitor (MBA'01J), CEO, Monitor-It.

What Will Be the "Killer App" for the Healthcare Consumer?

Marc joined MONITOR-it as CEO in 2009.  Prior to joining, he spent nine years at various leadership positions in the medical device sector at Johnson & Johnson, where he became seasoned expert in Medical Devices in general and Cardiology in particular. During his tenure at Johnson & Johnson Marc developed a comprehensive understanding of the value drivers and trends in the healthcare industry and in medical device technologies in particular.

Marc holds a Master Degree in Engineering from the Swiss Federal Institute of Technology (ETH) in Zurich, and an MBA from INSEAD.

MONITOR-it is a start-up combining new ways of healthcare delivery (remote patient monitoring) with thorough clinical strategies to develop a novel indicator for early detection of acute heart failure events.

Workshop 5 Coordinator: Aleksandar Ruzicic (MBA'97J), Senior Principal, IMS Consulting Group

Value Chain Disintegration - Winning strategy or tactical cost-cutting?

Aleksandar Ruzicic has worked in consulting since 1994, focusing on life sciences/healthcare, particularly the pharmaceutical/biotech sector. He is a Senior Principal at IMS Consulting Group, the world's leading, specialized advisor on critical strategic and commercial issues in life sciences. He advises international pharmaceutical/biotech, medical devices and other companies in the healthcare sector on strategic and operational topics from R&D to marketing and sales, particularly on new business models, and has published his insights continuously in a series of reports and articles.

Mr. Ruzicic has obtained a Master of Science in Chemistry from University of Zürich and holds an MBA degree from INSEAD.

He currently serves as Vice President of the INSEAD Healthcare Alumni Network which he co-founded in 2006 and as President of the INSEAD Swiss Healthcare Industry Club.